<SEC-DOCUMENT>0001104659-13-057588.txt : 20130730
<SEC-HEADER>0001104659-13-057588.hdr.sgml : 20130730
<ACCEPTANCE-DATETIME>20130730083812
ACCESSION NUMBER:		0001104659-13-057588
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130730
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130730
DATE AS OF CHANGE:		20130730

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OvaScience, Inc.
		CENTRAL INDEX KEY:			0001544227
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				451472564
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35890
		FILM NUMBER:		13994110

	BUSINESS ADDRESS:	
		STREET 1:		215 FIRST STREET
		STREET 2:		SUITE 240
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		617-500-2802

	MAIL ADDRESS:	
		STREET 1:		215 FIRST STREET
		STREET 2:		SUITE 240
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a13-17481_48k.htm
<DESCRIPTION>8-K
<TEXT>


<html>
<head>


  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<div style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 3.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">WASHINGTON, D.C. 20549</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FORM&nbsp;8-K</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">CURRENT REPORT</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">Pursuant to Section&nbsp;13 or 15(d)&nbsp;of the</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">Securities Exchange Act of 1934</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date of report (Date of earliest event reported): <b>July&nbsp;30, 2013</b></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">OvaScience,&nbsp;Inc.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Exact name of registrant as specified in its charter)</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Delaware</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">001-35890</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">45-1472564</font></b></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(State or other   jurisdiction</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">of incorporation)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Commission</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">File Number)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(IRS Employer</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Identification No.)</font></p>    </td>   </tr>  </table>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">215 First   Street, Suite&nbsp;240</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Cambridge,   Massachusetts</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="49%" valign="bottom" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">02142</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address of principal   executive offices)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Zip Code)</font></p>    </td>   </tr>  </table>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Registrant&#146;s telephone number, including area code: <b>(617) 500-2802</b></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Former Name or Former Address, if Changed Since Last Report)</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Check the appropriate box below if the Form&nbsp;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<u>see</u> General Instruction A.2. below):</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="2" style="font-size:10.0pt;">&#160; Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="2" style="font-size:10.0pt;">&#160; Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="2" style="font-size:10.0pt;">&#160; Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under the Exchange Act (17 CFR 240.14d-2(b))</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="2" style="font-size:10.0pt;">&#160; Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under the Exchange Act (17 CFR 240.13e-4(c))</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="border-bottom:solid windowtext 3.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\pselva\13-17481-4\task6160292\17481-4-ba.htm',USER='105344',CD='Jul 30 02:35 2013' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 8.01 Other Events.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On July&nbsp;30, 2013, OvaScience,&nbsp;Inc. (the &#147;Company&#148;) announced the appointment of Arthur Tzianabos, Ph.D., to the position of Chief Scientific Officer. The press release of the Company announcing such appointment is attached as Exhibit&nbsp;99.1 to this Current Report on Form&nbsp;8-K and is incorporated by reference herein.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 9.01 Financial Statements and Exhibits.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="9%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:9.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exhibit&nbsp;No.</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="87%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:87.66%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description</font></b></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:9.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:87.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Press   release dated July&nbsp;30, 2013</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="PB_2_064404_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\pselva\13-17481-4\task6160292\17481-4-ba.htm',USER='105344',CD='Jul 30 02:35 2013' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIGNATURE</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">OVASCIENCE,&nbsp;INC.</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date: July&nbsp;30, 2013</font></p>    </td>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Christopher M. Lindblom</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Christopher M. Lindblom</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vice President of Finance and Treasurer</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3<a name="PB_3_064438_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\pselva\13-17481-4\task6160292\17481-4-ba.htm',USER='105344',CD='Jul 30 02:35 2013' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a13-17481_4ex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 99.1</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="53%" valign="top" style="padding:0in 0in 0in 0in;width:53.24%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-weight:bold;"><img width="222" height="62" src="g174814mmi001.jpg" alt="GRAPHIC"></font></b></p>    </td>
<td width="46%" valign="bottom" style="padding:0in 0in 0in 0in;width:46.76%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">News Release</font></b></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">FOR IMMEDIATE RELEASE</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">OvaScience Appoints Arthur Tzianabos, Ph.D., to Chief Scientific Officer</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CAMBRIDGE, Mass., July&nbsp;30, 2013</font></b><font size="2" style="font-size:10.0pt;"> &#151; OvaScience</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">SM</font><font size="2" style="font-size:10.0pt;">, (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today the appointment of Arthur Tzianabos, Ph.D., to the position of Chief Scientific Officer.&#160; Dr.&nbsp;Tzianabos joins OvaScience from Shire Human Genetic Therapies, where he led the discovery and development of new therapeutics from concept through commercialization, as well as product expansion and business development efforts.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;Arthur&#146;s success in driving major scientific discoveries through clinical development to commercialization, and his diverse technical background in cell biology, will make him an excellent addition to our team,&#148; said Michelle Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience.&#160; &#147;Arthur also shares our commitment to solving medical problems in areas of high unmet need.&#160; Together, we are determined to help women with infertility by developing new treatments, the first of which we plan to make available in the second half of 2014.&#148;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dr.&nbsp;Tzianabos brings to OvaScience more than 20 years of experience in drug discovery and development, strategic planning, portfolio management, business development and alliance management.&#160; He joins OvaScience from Shire, where he most recently served as Senior Vice President and Head, Research and Early Development.&#160; During his eight years at Shire, he served in roles of increasing responsibility and was instrumental in the development of the human genetic therapies pipeline following Shire&#146;s acquisition of Transkaryotic Therapies,&nbsp;Inc. in 2005.&#160; Prior to Shire, Dr.&nbsp;Tzianabos was an Associate Professor of Medicine at Harvard Medical School and maintained laboratories at the Channing Laboratory, Brigham and Women&#146;s Hospital and the Department of Microbiology and Molecular Genetics at Harvard Medical School.&#160; His research at Harvard led to the discovery of a new class of immunoregulatory, T cell-dependent antigens, which formed the basis for technologies licensed by two biotechnology companies and Eli Lilly and Company for clinical development.&#160; During his time at Harvard, he served as a consultant to several biotechnology companies, including Genzyme Corporation and Eli Lilly.&#160; Dr.&nbsp;Tzianabos has published more than 80 scientific papers, book chapters and patents in the field of immunology, glycobiology and infectious disease, and was on the Board of Directors of bluebird bio and ArmaGen Technologies.&#160; He holds a B.S. in biology from Boston College and a Ph.D. in microbiology from the University of New Hampshire.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;OvaScience offers an exciting opportunity to translate the groundbreaking discoveries of the founding scientists and researchers in the fertility field by helping advance the development of products that have the potential to dramatically improve treatment for female infertility,&#148; said Dr.&nbsp;Tzianabos.&#160; &#147;I look forward to supporting the ongoing development and commercial preparation activities that are underway for AUGMENT</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">SM</font><font size="2" style="font-size:10.0pt;">, driving the preclinical work required to move</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\C901502\13-17481-4\task6160746\17481-4-mm.htm',USER='C901502',CD='Jul 30 05:33 2013' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">OvaTure</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">SM</font><font size="2" style="font-size:10.0pt;">&#160;into the clinic, and exploring new opportunities to expand the Company&#146;s product pipeline.&#148;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dr.&nbsp;Tzianabos succeeds Scott Chappel, Ph.D., who remains a member of the Company&#146;s Scientific Advisory Board.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About OvaScience</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">OvaScience (NASDAQ: OVAS) is a life sciences company focused on the discovery, development and commercialization of new treatments for infertility.&#160; The Company&#146;s patented technology is based on the discovery of egg precursor cells (EggPC</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">SM</font><font size="2" style="font-size:10.0pt;">), which are found in the ovaries.&#160; By applying proprietary technology to identify and purify EggPCs, OvaScience is developing potential next generation <i>in vitro </i>fertilization (IVF) technologies.&#160; The Company currently has two product candidates in development: OvaTure</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">SM</font><font size="2" style="font-size:10.0pt;">, which seeks to create mature fertilizable eggs from a woman&#146;s own EggPCs without the need for hormone injections, and AUGMENT</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">SM</font><font size="2" style="font-size:10.0pt;">, which aims to improve egg quality and increase the success of IVF.&#160; OvaScience&#146;s team of scientists, physicians and advisers includes recognized leaders in the field of reproductive medicine. For more information, please visit www.ovascience.com and connect with us on Twitter and Facebook.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Forward-Looking Statements</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">This press release includes forward-looking statements about the prospects for the Company&#146;s technology in addressing female infertility, the Company&#146;s strategy, future plans and prospects, including statements regarding the development and planned launch of the Company&#146;s product candidates, including AUGMENT. Any statements in this release about our strategy, plans, prospects and future expectations, financial position and operations, and other statements containing the words &#147;anticipate,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;target,&#148; &#147;aim,&#148; &#147;potential,&#148; &#147;will,&#148; &#147;would,&#148; &#147;could,&#148; &#147;should,&#148; &#147;continue,&#148; and similar expressions, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: our expectations regarding the regulatory approvals required for AUGMENT; the science underlying our two product candidates (AUGMENT and OvaTure), which is unproven; our ability to obtain, maintain and protect intellectual property utilized by our products; our ability to obtain additional funding to support our activities; our dependence on third parties; the successful development of, and ability to obtain regulatory approval for, our product candidates; our ability to commercialize our product candidates, including AUGMENT, on the timeline we expect, if at all; competition from others; and our short operating history; as well as those risks more fully discussed in the &#147;Risk Factors&#148; section of our most recently filed Quarterly Report on Form&nbsp;10-Q or Annual Report on Form&nbsp;10-K. The forward-looking statements contained in this press release reflect our current views with respect to future events.&#160; We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our view as of any date subsequent to the date hereof.</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Contact:</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Theresa McNeely</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">EVP, Strategic Corporate Communications</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">OvaScience,&nbsp;Inc.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">tmcneely@ovascience.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">617-299-7356</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\C901502\13-17481-4\task6160746\17481-4-mm.htm',USER='C901502',CD='Jul 30 05:33 2013' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g174814mmi001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g174814mmi001.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!#`0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P``1"``^`-X#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V:JU[?VNG
MP^;=3+&I.!GJQ]`.]32R+#$\KG"H"Q/L*X^.6*^6\U_5\M9P'$$(YW8[8[]O
MJ:J*N;TJ<6G.;M%?U8T9/&-JBF7[%=&!3\TI4!1^M7=+\2:3J[F.SO$:4#)C
M8X;'TKS>U&K_`!"U#>K[;6)L&/)6W@7/'RY^=B/\BMN3X2V0MF,6H3-<@?*6
M550GT(`R!73*C3CI.5F<LL1&HOW5/3O?_@'H5%>9^%M<UOPWKR^'=?$CPRN$
M@D<E@A)P,,>JGI7IE85*;INPJ=135PHHHK,T"BBB@`HHKRC6-<\0^,?%,^B:
M%<-;6L#,I*/LR%."S,.<9Z`5K2I.HWK9(RJ5%!=VSU>BO*G\`^--.4W-CKOF
MS+R$2X=2?^^N#^->F:<;@Z;:F[S]H,*>;GKNP,_K14IQBKQE<(3E+1QL6:**
MBN&E2VE:!`\JH2BDX#-C@?G61J2T5Q?@;6/%6I7]Y'KUHT4"+E&:'R]KY^Z/
M48S^5=I5S@X2Y61":FKH****@L****`"BBB@`HHHH`**;)(D2%W8*J]2:2*:
M*92T4BN`<$J<X-`%+7BXT.\V9!\L\CT[_I7!>+KEX/A[ID,#!1,Y+MNZ#G(Q
MWY->CW=NMW:2V[_=E0J?QKS#Q.LLGA6329OW=Q93!U7'WEZ=?QS71A[<ZOW-
MYQ<\%.,=T[_([+P#;)!X/LI%0*UPIE;\2<?I@5T=<-X#\3:>=/M],>=83M"P
M1R<$,!\RD]SG)'L<5W-16351W..BTX*QD>(-(L]2M5DN6$;P9*2$XP3P!G_>
MVGZ@5QWB+Q9XE\*ZG8?:?*FL)HT8@Q?-D`;UW>O?\:Z7Q;,MU%:Z%&Q,]_,A
M95_@B5@SL?0<8^IJ?Q=X?3Q)H$UG@"=?WD#G^%QT_`]/QK2G)1Y>?5,BI%N_
M)N:UK=0WMI%=6[AX9D#HP[@C-<"/&FLZWXX.D:$\*V*/M>5HMWRK]]\_H/PK
ME-.\:WNC>$K[0'5UN0YCA<]8E.=X/N.<?7VKL_`OAF31_"5S>LA6_OH&9?5%
MVG8/Z_\`ZJU=%44W+7HO\S)575:4?5_Y&;K_`(^UC4]:;1O"D9.UBGFJ@9Y"
M.I&>`H]:$U7X@>%PM[K$'VZP!!F`*,R#N<KR/QR*K_!YK47^HJ^!=F--F>NS
M)W8_'%>HW+0+:RM<E1`$/F;^FW'.?;%%64:4O9J*:_$*<95(^T<M?P.!\">,
MM6\1>)+FUNY4:U6)I(U$84CYAC)'L:YO4H-;^'WBV?4[>$O;3.Q61E)CD1CG
M:Q'0U/\`"HQ?\)A>&+B+[.^S/]W>,?I7KK)%<1%75)8W'((!#"JJS5&JTEHU
ML*G!U::;>J9QV@_$[1M6=(+P-I]PW`\PYC)]F[?CBN@\0:]:^'=(DU&ZRRK@
M1HIYD8]`*X?XD>#M(LM(?6+")+25'57C3A),G'`['Z>]<WKEW>WGP[T%YW9T
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M^]_4Z"[UWQWX-FAGUETO;21L'.&4^VX`$'ZUO>,?&5UI_AW3-5T62,+>MUD3
M=QMSCZYK.O\`P)XQU2U-K?>)8;B$D$HX;&1T[5G>.-(GT'P)HVFW$R3207#@
MN@('()[_`%J4J4Y1VO?H4W4A&6]O,MQ:UX_\464=QI$"VMLJ`&7Y5,S#[Q&[
MMGT_.H/#_CKQ!IOB./1_$69%DD$3^8@5XB>AR.HZ5W_A-0/"6E```?98^GTK
MSSXA`#XC::0`"5@S[_.:FFXSE*FXJVHYJ4(JHI.^AU/CCQR/#(2RLXUFOY5W
M8?[L:]B?4GL*YVW7XHW\8O4E:)6^98W\M,C_`'2/YU2U=HD^,BMJ./(%S%@O
MTQL&W\,UZ_42<:,(VBFVKZEQ3JRE=M)=CCSXKU#P_P"#5O\`Q%;_`/$R,C1)
M"`%\PYX/'&,<DBN=M+GXD>([?^U+.=+:W?F*,;4##V!!)'N:?\9/-WZ5U\K$
MO_?7R_TJ;2_#OC.[TJUGLO%D0MGB4Q*N["KC@=.W2M(J*IJ>EWW(DY.HX:V7
M8N>#?&-YJ^H3^'?$,"B\4,`=NW?C[RL/7OQ7<P6L%JI6"%(@QR0HQDUP6C>`
M-;L_%=OKFH:M;W+HY:0@-N?Y=OI7H5<U?DYO<V.BCS\OOA65K.@6VL)EF,4P
M&/,49R/0CN*U:K_;K?\`M$:?O/V@P^=MP?N9QG/UK!7Z'3"I*G+FB[,\QU+X
M>:W83M+IC13VS'<\><DGL2IQGZCFM*QU/QK;6XLK30XDSG][()6P3W`8\?3.
M*]$HKH^L-JTE<YY4ES.4=/0Y_0?#9LKB34]0GENM1G`\R60CI_=`'``]!704
M45A*3D[LTC%15D</K'P^BU+QM;:J`HLG_>7<?]YUZ<>C=_H?6NW`P,#I45U=
M06-L]S<R".),;F()QDX_K4M5*<I)7Z"C",6[=3S;Q%\.M2@U@ZOX7G$3LQ<Q
M;]C(QZ[3TP?0TU/#/CKQ"8[7Q!J/V>P!'F*KKN<>F$Z_C7IE94OB*PBU1M-Q
M</<(RJWEV[LJENF6`P.M;1KU&K6NUUMJ8NA33O>U_N.5\%^!M2\.Z_=7=R\!
MMI(GCC".6;!8$9X]!6</#/C_`,/.T6BZB+FUR=BAUP!_NOP/PKU"HC<0K<+;
MF11,REU3/)48!./Q%3]8FVVTF/V$$DD['ETG@[QOXHN(QX@O!#;HV?F=3CW"
M)QGZUW-WX1TRZ\+IX?VLEO&H$;C[R,/XOKG.?J:M/XBTJ.0HUT.$D<G:<`1D
M!^W8D5=BNH)Y)(HI5=XL;U!Y7(R,^F11.K4=M+6'"E35^MSRZW\(^//#,LD>
MB7:2P,<_)(NT^Y1^`:Z;POI_B\2WLOB.Z#K+!LBBWJ0K>N%&!76S2K!`\SAB
MJ*6(52QP/0#K6+'XST>03,&NE6`$RL]K(H3`S@DC@\]*IU9U$_=7K8E4H4W\
M3]+F-\/_``?J?ABZOI+]X&6X10GE.3T)ZY`]:R]>^'&I6VL-JWABY$3,Y?RM
M^QHV/7:>A'L:]*!R`1WI:GZQ-3<^Y7L(<JCV/,18?%*Z40R7BP+TW^9&I_-1
MFK^O>"-9U+PGINEK>17%W;2L\TTKMALY[D$GK7?T4?6)7322MY!["-FFVRAH
M=E+IVA65E.5,L$"1N5.1D#'%<GXL\&:IK?BVSU6U>W$$"QA@[D-\K$G`Q79V
M=]!?QO);N66.5XF)!&&4E6'YBJFI:_9:9<+;3">69D\SRX(6D94SC<<#@9J8
M3G&;:W*G&$H)/8Q/&W@6+Q.$NK:58+^)=H9A\LB^C?T-<W;Z7\3["$6<%SNB
M485FEC?`]BW->H1R++$LB9VN`PR,<'VJ*UN[>]A\ZVD$D>XKN`(Y!P1^8JHU
MYQCRM)I=R948RES)V?D<N_A&\USP;%IOB"ZWZBCM(MP#OV-DX],C'&*Y>S\-
M?$/PZ&MM*N4>WW'`25"GU"OTKU>BB.(DKJR:[!*A%V=W<X+0=!\:S:W;7^OZ
MF!;V[%OLXDSO.".B\=Z[VBBLIS<W=FD(*"L@KC/%R7JZG=36:W"O_9@19(%.
M03.F0".^,UV=%$)\CN$X\RL<5=:)*MYK$$5UJ@@@LDGM@+F0_OB'R0<\GY5X
MZ<].:S6NDGN-2.JS:L9Q#";9;8RX64PJ3@+P&W=FX_6O1ZK6]C!:W-S<1*1)
M=.'E).<D`*/IP*U5;N9NCV..A@UZ6WU6[D:[.J6UK!Y"!V";S$-Y5?NLV<^H
MS1:1#4+R.ST2_P!5$4MLXO)9VD_=28!1LOT?=U`XQFNZI*7MO(?LO,X:XG\0
M7^D7NH7*7%K-:(EK'!"3^\D#KYDN!U!Z#VS1=6U^+34=46;4?MD&K%;=1(^W
MRO,48"="I!/:NZHH]MV0>R\S@-,E^V>,=DU^&-O>2L)6N7*W(P=J(GW?ESC@
M_P`)K6BLK\Z]KMW;7%Q$R%#%#M'ES-Y7&21SSZ&KUMX5L;6>%EFNF@MI3-!;
M/+F*)SGD#&>YQD]ZVZ<ZJO[O84*;MJ>6PW&JG2KF2+4;C[:;)A/;JEP93)D<
MG=\JL#G[N,YXK:U'3;#2_$6G2W4NH);26LBF43RN?,W(0,C)&>>.AQ7<44.O
M=[`J.FYYW=_VF7EN`ET9H[745C?8VX?O%V`?@.*MP6%J?%.JVUS<W]M<7BQ&
MW9))!NS'\QR..#Z]*[FFR)YD;)N9=P(RIP1]*7MNE@]CYG+^&I]5U>]^T7\A
M6+3`UK^[?Y;F8'#2>XP!@>I/I5?4+>X?1/%B+#+NEG/E@(26^1.1ZUU5C8V^
MFV45G:ILAA7:JYS^9[FIZ7M+2ND5[/W;-G":Y97VEO=0:;<:DT<UC&['S7D(
MD\]%)!YP=I;('Y5/J4-O8:L]KJ=QJ<.G);@V;022MND))?++DE^F`>,5VM%/
MVSZB]EV.%L]8U'3]PUIKM9KC2T\@>4S%I`TG91@/@IFLF6XN+AK.RO;]UDEL
M[4M-+<R1BU(QO5U'!9_]K%>H5BWGA>RO+BXD:>ZCCNR#<P1RXCF(`'(QGH`#
M@C-5&K&]VK$2I2M9.YST6FSVUF^HV[7T=RNM.%C5WV>49R"-G0J5).<>^:O^
M*9+.VO\`[7#?W=AJJ08C:&%I%G7)(0K@AN<^A&:ZL*%``&`!@"EJ/:W=V:>R
MLK(XBWN7N-79O$SWUI<.L)M(86D6+E1NQLZMOR#GMBLNXN-7,=JE]<3P6;&Y
M_>2^<H\SS2%W&/YA\N-N>*]+HJE6MT)=*_4X."QOM0M]1>ZU#4)FMM/A:VDB
M:2$/)L<E@O!)X'!_*I+.X$NI9\07&H13E8#9(ID6-@44D_)P6WYR&KN**7MO
M(?LO,\]T"?4WURV:]U!XKWSW%S;LDY+CG"X_U84<$$8Z5Z%1145)\[O8J$.1
$6N?_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
